Hughes and Associates

08/12/2026

Our latest Q2 2026 Biopharma Market Update looks at the forces shaping the market, from renewed venture investment and M&A activity to easing layoffs and the continued importance of specialized scientific talent.

We also explore what these shifts may mean across Clinical Pharmacology, Pharmacometrics, DMPK, QSP, Bioanalysis, and related quantitative and translational sciences, where hiring dynamics continue to follow their own patterns.

Read the full market update: https://www.haallc.com/2026/08/12/biopharma-market-update-2026/

Read the Biopharma Market Update 2026 to understand the impact of recent M&A activity and the selective recovery in the sector.

08/05/2026

One thing we've been noticing as we've tracked the biopharma market this year is that investment activity and hiring aren't moving at the same pace.

There's certainly been a lot of positive momentum across the industry. Venture funding has picked up, M&A activity remains active, and the IPO market has continued to reopen. At the same time, many large pharmaceutical companies are still restructuring, while clinical-stage biotech organizations continue investing in pipeline growth.

What we've found interesting is where hiring has remained the most consistent.

Across Clinical Pharmacology, Pharmacometrics, DMPK, QSP, and Bioanalysis, demand has stayed relatively resilient compared with the broader market. These are functions that sit at the intersection of translational science and development strategy, making them difficult to put on hold, and often even harder to hire for when demand returns.

We've also noticed that much of this hiring continues to come from clinical-stage biotech. In our own 2026 market tracking, roughly 60% of the Clinical Pharmacology leadership opportunities we identified came from biotechnology companies.

It's an interesting reminder that while the overall market may be improving, hiring doesn't always recover in the same way across every function.

Some areas rebound quickly. Others remain highly competitive because the talent has always been limited.

It'll be interesting to see how this continues to evolve as more companies move programs through development.

Have you been seeing similar hiring patterns within your organization or across the industry?

07/29/2026

Drug Metabolism & Pharmacokinetics (DMPK) hiring continues to evolve as biotechnology organizations seek experienced scientific leaders who help guide critical drug development decisions across increasingly complex pipelines.

Our latest 2026 DMPK Talent Market Report explores where hiring demand is strongest, the skills organizations are prioritizing, and why compensation, work models, and scientific leadership continue to evolve across the industry.

▶️ Watch this short clip for key insights from the report.

07/22/2026

The role of Drug Metabolism and Pharmacokinetics (DMPK) continues to expand as organizations seek scientific leaders who can contribute far beyond traditional ADME and pharmacokinetic responsibilities.

Our latest DMPK Talent Market Report 2026 shares insights from DMPK leadership and scientific openings tracked by Hughes & Associates throughout 2026, highlighting trends in hiring demand, compensation, work models, therapeutic modalities, and the technical and leadership capabilities organizations are prioritizing.

Whether you're planning your next hire or benchmarking your talent strategy, these market insights provide a practical look at today's competitive DMPK talent landscape.

📖 Read the full report: https://www.haallc.com/2026/07/22/dmpk-talent-market-report-2026/

07/15/2026

One trend that stood out across the recent DMPK openings we reviewed is how the role continues to expand beyond traditional ADME and PK responsibilities.

Across the 2026 job postings we've reviewed, organizations are consistently looking for professionals who can combine strong scientific expertise with strategic thinking, cross-functional collaboration, and translational decision-making.

Some of the capabilities that appeared most frequently include:
• DMPK strategy and project leadership
• ADME study design and interpretation
• PK/PK-PD modeling and simulation
• Cross-functional collaboration across Discovery, Clinical Pharmacology, Toxicology, CMC, and Regulatory
• Human PK prediction and first-in-human dose projection
• Regulatory support for INDs, CTAs, NDAs, BLAs, and Investigator Brochures
• Bioanalytical data interpretation and decision support
• CRO and external partner management
• Quantitative modeling platforms such as Phoenix WinNonlin, NONMEM, Simcyp, GastroPlus, PBPK, MATLAB, and R
• Translational drug development supporting candidate selection, dose optimization, and clinical strategy

What stood out wasn't any single technical skill. While subject matter expertise is critical, organizations also appear to value individuals who can integrate DMPK knowledge across the entire development process, from lead optimization through clinical translation, while helping teams make better-informed development decisions.

Does this reflect what you're seeing within your own organization?

07/10/2026

With our ongoing review of Clinical Pharmacology hiring activity, there's one theme that seems to come up more often than before.

Technical expertise remains the foundation, but many of the opportunities we've reviewed also emphasize something else: the ability to translate quantitative science into development decisions.

Across recent Clinical Pharmacology openings, we continue to see strong demand for capabilities such as PK/PD, Population PK, exposure-response analysis, and Model-Informed Drug Development. Alongside these technical requirements, many organizations also appear to be looking for professionals who can contribute beyond the analyses themselves.

Responsibilities such as supporting dose selection, contributing to regulatory strategy, partnering with cross-functional teams, and helping guide development decisions were common themes across many of the roles we reviewed.

It's an interesting reflection of how the function continues to evolve.

As drug development becomes increasingly complex, Clinical Pharmacology appears to be playing an even more integrated role, helping connect quantitative science with the broader decisions that move development programs forward.

It will be interesting to see how this continues to shape the Clinical Pharmacology function in the years ahead.

Have you noticed a similar shift within your organization or throughout your career?

If you'd like to explore the full discussion, you can read our latest Clinical Pharmacology article on our website. https://www.haallc.com/

07/08/2026

Clinical Pharmacology hiring continues to evolve as organizations prioritize experienced scientific leadership, quantitative expertise, and greater hiring precision.

Our latest Q2 market intelligence highlights where demand is strongest, how teams are being structured, and the market dynamics influencing hiring decisions across biotech and pharmaceutical organizations.

▶️ Watch this short clip for key insights.

07/01/2026

What do today's Clinical Pharmacology job openings tell us about the talent market?

We analyzed 30 recent Clinical Pharmacology opportunities across biotech and pharmaceutical organizations to identify recurring hiring patterns.

Our analysis explores trends in:
• Talent demand
• Compensation
• Work models
• Scientific capabilities
• Leadership expectations
• Emerging AI signals

These observations provide a snapshot of how organizations are building and evolving their Clinical Pharmacology teams.

Browse through the carousel to see the highlights.

If you're evaluating your hiring strategy or workforce plans, we'd be pleased to discuss what we're seeing across the market.

📖 Read the full Clinical Pharmacology Market Intelligence Report:
🔗 https://www.haallc.com/2026/06/25/clinical-pharmacology-talent-market-report-2026/

06/25/2026

The Clinical Pharmacology talent market continues to evolve, and so do the expectations for hiring scientific leaders.

Our latest Clinical Pharmacology Talent Market Report 2026 shares insights from Clinical Pharmacology leadership openings tracked by Hughes & Associates throughout 2026, highlighting trends in hiring demand, compensation, work models, and the technical and leadership capabilities organizations are prioritizing.

Whether you're planning your next hire or benchmarking your talent strategy, these market insights provide a practical look at today's competitive landscape.

📖 Read the full report: https://www.haallc.com/2026/06/25/clinical-pharmacology-talent-market-report-2026/

Explore the Clinical Pharmacology Talent Market Report 2026 and discover key workforce trends in the pharmaceutical industry.

06/10/2026

We're grateful for the opportunity to speak with scientific leaders, hiring managers, HR leaders, and TA teams across the translational sciences community every day. These conversations continue to provide a valuable perspective on how hiring priorities are evolving.

There's one hiring topic that appears to be gaining momentum: the conversations we're having are becoming less about filling a position and more about identifying the expertise, experience, and leadership needed to support future objectives.

Many organizations still ask, "How many people do we need?"

But increasingly, the first question seems to be, "What capabilities do we need to support our next milestone, program, or strategic objective?"

That shift makes sense, especially in highly specialized areas such as Clinical Pharmacology, Pharmacometrics, QSP, DMPK, and Bioanalysis, where the impact of a hire often extends well beyond a single position.

As development programs become more complex and scientific functions become increasingly interconnected, organizations often appear to be thinking more carefully about the capabilities required to support long-term success, not just immediate hiring needs.

As hiring priorities continue to evolve, capability planning may become just as important as workforce planning.

Is this something you're prioritizing within your organization right now?